denoforest is obviously the alter ego of "eastmanpicks", the renowned pumper of DNDN, which seems to have made a new alltime low of 2.04 today.
Poor deno. Sitting on the pier waiting for his DNDN ship to come in, not realizing that it has already sunk. By the way, not a single particle of his post (which is strangely similar to other posts under other id's) is true.
Looks like all those who shorted it today are underwater here. In an act of blind faith - and because it seemed to be arbitraged @ 60, I bought some more @60 and have sold them (probably too soon) after hours for a profit.
GILD having offered a cautionary example after a huge beat. So we should all be prepared to make a judgment as to what constitutes "good" earnings, and I will arbitrarily say that anything close to breakeven is good, which will motivate me to buy into any dips.
You're right. Buying back 4% of the float is real bad news for investors. Particularly on the heels of a huge earnings beat, this should arouse suspicion among the feeble minded.
Sdt, I think you won everyone's respect for your candor here. By the way, I don't think this stock is going to shoot up in the near future, although it may flirt with 100 at some point if they can sell the call options. Sorry for the outcome, but remember that your loss is tax deductible, which makes any future short term capital gains taxfree for a while. Good luck.
Well, JNJ has just asked the FDA for permission to combine Sovaldi with their proteasome inhibitor Olysio, which may make the treatment marginally more effective than Sovaldi alone for some, but will bring the cost per treatment up to $140,000. A piece in Barron's speculates that Gilead could offer the same benefit by combining Sovaldi with ledipasvir, their own inhibitor. Perhaps we could do this at the bargain price of, say, $139,999.99.
Well, they seem to just have dropped 10 bucks a share in spite of an earnings report that was full of the usual PR puffery to go along with a lot of red ink. The real strength of the company is Musk's genius for PR.
GILD will break above 80 definitively on May 19, after the May 80 calls have expired worthless. Although it will flirt with 80 in the interim, I believe.
Interesting info, bigcire. On a different subject, what is your rationale for installing the system? How much does it cost you installed? How much does it save you? (I'm thinking of doing the same thing myself.) Thanks in advance.
With all due respect, TSLA seems like a much riskier bet here than PCYC. And I'd say that PCYC is displaying a lot more stability lately. A lot of the retail speculators have been driven out of PCYC, but I think that there are still a lot of weak hands in TSLA who have been convinced that there is strong support at 200, which I don't believe. When they drop it, they will drop it hard I think.
Massive short positions, as you must know, are always dangerous. Gundlach, like all the hedge fund geniuses (Jim Chanos comes to mind) only share their brilliant insights with the public when they are bailing from their positions. They're not talking their book; they're talking their old book. And some of you are buying it.
First of all, "$1,000 a pill" is an idea created by the press, not by Gilead. Second of all, if the company had really suggested a price per pill, nothing would have been more cynical than setting the price, as you suggest, at $999. How about $999.99? The press would have loved that. Or, since we are following the lead of Super Juicer, why not price half a treatment at $19.95, include the second half free if they order right away, but bill them $54,000 for shipping and handling?
Well, we know that he's an idiot. But mostly, like all of those who post nonsense here about generic Zytiga, "half a drug", seizures, etc. that he's a diehard Dendreonite. He's like an old Russian sitting in a Paris café in the 20's daydreaming about the return of the czar, when he will get all of his expropriated property back.
Like many of the hopeful retail investors, sdt got scared out of this stock on the earnings bear raid. Unlike many of us, he was absolutely frank about his entry point at140. As it began to sell off, he said that it was going to 120 and then 110, which I scoffed at. Some posters acused him of being a shadow short. After all, how could you believe the stock was going down and just sit on your position? Perhaps because he was afraid of missing a 10 point rebound. Only recently did he disclose that his 1,000 shares of PYCY was his only stock position and that he was on margin. On three separate occasions - most recently on the day before the earnings release - i urged him to take some off the table. (i really thought he should have sold his entire position and retired from the field until things became clearer, but I knew he wouldn't go for that.) It will probably be a long time before he returns to the stock market. Like many retail investors, he is probably disillusioned and realizes that he has been gamed by the pros. Unfortunately, he took his position in PCYC on Feb 28, just three days after the biotechs had made their high. Which was a little like being posted to the Eastern Front just before the Russians retook Stalingrad. Too big a gamble on a single stock of course. It's been demonstrated repeatedly that you need about 40 stocks in your portfolio to offset the risk of a drop in any one stock. When taking a new position, it also makes sense toedge your way in gradually. My own approach is to take a partial position and not add to it until you're ahead. I was in and out of PCYC three times between 18 and 20 before I caught a good run up to 38. Later I got two more good runs out of it Although I took my profits in my IRA, I once again stayed too long in this position out of a reluctance to pay taxes on my gains. It's important to note where you screw up. Nothing is more dangerous in investing than the need to be proven right.
Rather than the sheer number of houses sold, perhaps Gundlach should consider the impact of very low inventories on the price of the new homes sold ... particularly for the higher end homebuilders.
This recovered much more quickly than I thought it would from the earnings bear raid. (GILD lingered a few days before bouncing back.) Looks like my sub 85 buy orders will not get filled. However, considering that the Amex Biotech Index was up 2.5% today, I still think I'll be able to add shares in the 92 area.